Press release
Plaque Psoriasis Clinical Market Projected to Reach USD 27.6 Billion by 2034
Plaque Psoriasis Clinical
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73631
Over the past decade, advancements in biologic and targeted small molecule therapies have revolutionized psoriasis management. From TNF-α inhibitors to IL-17 and IL-23 inhibitors, treatment options have expanded significantly, providing long-term control and improved quality of life. The global plaque psoriasis clinical market continues to evolve, fueled by ongoing research, expanding biologic portfolios, and increasing access to personalized dermatology care.
Market Overview
• Market Size (2024): USD 11.5 billion (estimated)
• Forecast (2034): USD 27.6 billion
• CAGR (2024-2034): ~9.2%
Key Growth Drivers:
• Rising prevalence of psoriasis, particularly in developed and industrialized nations.
• Growing availability and adoption of biologic and biosimilar therapies.
• Expanding clinical research into novel immune targets and oral small molecules.
• Increasing patient awareness and demand for effective, long-term management.
Challenges:
• High treatment costs of biologic drugs.
• Limited access to advanced therapies in developing regions.
• Psychological burden and stigma impacting patient adherence.
Leading Companies:
AbbVie Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., Johnson & Johnson, Bristol Myers Squibb, UCB Pharma, Pfizer Inc., Leo Pharma A/S, Sun Pharmaceutical Industries Ltd.
Segmentation Analysis
By Treatment Type
• Biologics (TNF Inhibitors, IL-17 Inhibitors, IL-12/23 Inhibitors, IL-23 Inhibitors)
• Small Molecule Drugs (Apremilast, JAK Inhibitors, PDE4 Inhibitors)
• Topical Therapies (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Phototherapy
• Others (Combination & Novel Therapies)
By Route of Administration
• Oral
• Injectable
• Topical
By Severity Level
• Mild
• Moderate
• Severe
By End User
• Hospitals & Dermatology Clinics
• Specialty Pharmacies
• Research & Academic Institutes
Summary:
Biologic therapies dominate the market, accounting for the largest revenue share due to their high efficacy and durable response rates. IL-17 and IL-23 inhibitors represent the fastest-growing class, while oral small molecules are gaining traction for their ease of use. Topical and phototherapy treatments remain preferred for mild cases, especially in primary care settings.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market
Regional Analysis
North America
• Largest market share in 2024 due to high diagnosis rates, advanced healthcare infrastructure, and strong reimbursement frameworks.
• Major contribution from the U.S., supported by new biologic approvals and patient access programs.
Europe
• Significant market presence with robust adoption in Germany, the UK, France, and the Nordic countries.
• EMA support for biosimilars driving affordability and wider access.
Asia-Pacific
• Fastest-growing region (CAGR ~10.5%) driven by rising prevalence, improving healthcare infrastructure, and growing access to branded and biosimilar biologics.
• China, Japan, and India emerging as key growth markets.
Middle East & Africa
• Early-stage adoption of biologics, primarily in GCC nations due to strong healthcare investments.
• Limited access to advanced treatments in developing sub-regions.
Latin America
• Moderate growth, led by Brazil and Mexico through public health initiatives and expanding dermatology networks.
Summary:
While North America and Europe dominate, Asia-Pacific is poised for the fastest growth, supported by biosimilar expansion, dermatology awareness, and increasing investment in specialty care.
Market Dynamics
Key Growth Drivers
• Expanding portfolio of next-generation biologics targeting IL-23 and IL-17 pathways.
• Increasing R&D in oral small molecules and JAK inhibitors.
• Wider use of digital dermatology tools and teledermatology consultations.
• Government initiatives promoting chronic disease awareness and treatment accessibility.
Key Challenges
• Affordability barriers in low- and middle-income countries.
• Long-term safety and efficacy monitoring of novel biologics.
• Patient non-compliance due to chronic disease fatigue or side effects.
Latest Trends
• Rise of biosimilar competition enhancing cost-effectiveness and accessibility.
• Integration of AI-based imaging and digital diagnostics in clinical dermatology.
• Increasing research into microbiome-targeted therapies and RNA-based treatments.
• Emergence of personalized and precision dermatology guided by genomic data.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73631
Competitor Analysis
Major Players:
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• UCB Pharma
• Pfizer Inc.
• Leo Pharma A/S
• Sun Pharmaceutical Industries Ltd.
Competitive Landscape:
The market is highly competitive and innovation-driven, dominated by companies like AbbVie (Skyrizi, Humira), Novartis (Cosentyx), and Eli Lilly (Taltz). The shift from TNF inhibitors to IL-17/23 pathway inhibitors marks a major therapeutic transition. Biosimilars and small molecules are intensifying competition by offering cost-effective alternatives. Strategic mergers, partnerships, and pipeline expansions are central to maintaining leadership in this evolving field.
Conclusion
The plaque psoriasis (psoriasis vulgaris) clinical market is projected to grow from USD 11.5 billion in 2024 to USD 27.6 billion by 2034, at a CAGR of 9.2%. Fueled by advancements in biologic and small-molecule therapies, increased disease awareness, and expanding healthcare access, the market is on a strong upward trajectory.
Despite cost and access barriers, ongoing R&D in targeted immunotherapies, AI-assisted dermatology, and biosimilars ensures continued innovation. With Asia-Pacific emerging as a high-growth region and biologics evolving toward higher precision and safety, the global outlook remains highly positive.
Key Takeaway: Companies that invest in next-generation biologics, biosimilar expansion, and digital dermatology innovations will lead the transformation of chronic skin disease management through 2034.
This report is also available in the following languages : Japanese (尋常性乾癬(尋常性乾癬)臨床), Korean (플라크 건선(Psoriasis Vulgaris) 임상), Chinese (斑块状银屑病(寻常型银屑病)临床), French (Psoriasis en plaques (psoriasis vulgaire) clinique), German (Plaque-Psoriasis (Psoriasis vulgaris) Klinisch), and Italian (Psoriasi a placche (psoriasi volgare) clinica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market#request-a-sample
Our More Reports:
Solar Aluminum Alloy Frame Market
https://exactitudeconsultancy.com/reports/75231/solar-aluminum-alloy-frame-market
Photovoltaic Panel Aluminum Frame Market
https://exactitudeconsultancy.com/reports/75232/photovoltaic-panel-aluminum-frame-market
Healthcare AI Computer Vision Market
https://exactitudeconsultancy.com/reports/75233/healthcare-ai-computer-vision-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Clinical Market Projected to Reach USD 27.6 Billion by 2034 here
News-ID: 4209893 • Views: …
More Releases from Exactitude Consultancy
Pulmonary Atresia Diagnostics & Treatment Market Expands as Advances in Pediatri …
Pune, India, November 14, 2025 - The Pulmonary Atresia Diagnostics & Treatment Market is experiencing steady global expansion as advancements in pediatric cardiology, neonatal critical care, imaging technologies, catheter-based interventions, and surgical reconstruction significantly improve patient outcomes. Exactitude Consultancy forecasts strong growth through 2034 driven by rising congenital heart disease (CHD) incidence, increased newborn screening, and growing availability of specialized pediatric cardiac centers.
Download Full PDF Sample Copy of Market Report…
Trauma Fixation Devices Market Accelerates as Road Injuries, Sports Accidents, a …
Growing incidence of fractures, advancements in internal and external fixation systems, and expanding orthopedic infrastructure are driving strong global demand for trauma fixation devices.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/50182
Introduction
The Trauma Fixation Devices Market is witnessing robust global growth as trauma cases-including fractures, dislocations, crush injuries, and complex orthopedic damage-continue to rise due to road accidents, falls, occupational injuries, sports activities, and aging populations.
Trauma fixation devices…
Medical Marijuana Market Surges as Legalization And Chronic Pain Management
Pune, India, November 14, 2025 - The Medical Marijuana Market is expanding at an unprecedented pace as increasing global legalization, rising clinical acceptance, and growing demand for cannabis-based therapies drive industry transformation. Exactitude Consultancy forecasts strong growth through 2034, fueled by advancements in research, improved regulatory frameworks, and widespread adoption of medical marijuana for chronic pain, cancer care, neurological conditions, and mental health management.
Download Full PDF Sample Copy of Market…
Renal Cancer Drug Market Accelerates as Immunotherapy And Targeted Therapy
Pune, India, November 14, 2025 - The Renal Cancer Drug Market is experiencing powerful global growth as rising incidence of kidney cancers-especially renal cell carcinoma (RCC)-drives demand for cutting-edge immunotherapies, targeted therapies, and precision oncology solutions. Exactitude Consultancy forecasts strong expansion through 2034, fueled by advancements in immune checkpoint inhibitors (ICIs), VEGF/VEGFR inhibitors, combination regimens, and personalized treatment protocols.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51880
Key Takeaways
• Market projected…
More Releases for Psoriasi
Pulp and Paper Market Growing from USD 351.7 Billion in 2024 to USD 518.2 Billio …
Introduction: The Timeless Industry Reinventing Itself
For centuries, the pulp and paper industry has played a vital role in global communication, education, packaging, and hygiene. Despite the digital age's influence, this market continues to evolve-driven by sustainable packaging demand, e-commerce growth, and the transition toward recyclable materials. As environmental awareness grows and plastic bans expand globally, pulp and paper products are becoming central to the circular economy.
According to Exactitude Consultancy, the…
Gaucher Disease Clinical Market to Reach $3.9 Billion by 2034, Growing at a 6.5% …
Introduction
Gaucher Disease (GD) is a rare inherited lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase, resulting in the accumulation of harmful fatty substances in organs such as the spleen, liver, and bone marrow. Though historically considered a niche orphan indication, the disease has gained major attention in the biotechnology and pharmaceutical industries due to increasing diagnosis rates, precision medicine innovations, and strong clinical research activity in enzyme…
Phototherapies for Psoriasis Market Set to Witness Significant Growth by 2025-20 …
Introduction
Psoriasis is a chronic autoimmune skin condition characterized by rapid skin cell turnover, leading to scaling, inflammation, and plaques. Affecting millions globally, psoriasis is not only a dermatological concern but also a systemic disorder linked to comorbidities such as arthritis, cardiovascular disease, and metabolic syndrome.
Phototherapy has long been an established treatment option for moderate-to-severe psoriasis, leveraging controlled ultraviolet (UV) light to slow skin cell growth and reduce inflammation. Recent advancements…
Chronic Plaque Psoriasis Market is expected to double, reaching USD 36 billion b …
Chronic plaque psoriasis is the most common form of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune disease characterized by raised, inflamed, and scaly skin patches that significantly affect patients' quality of life. While topical therapies and phototherapy have long been standard treatments, the advent of biologics and targeted small molecules has transformed the market.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71377
With…
Generalized Pustular Psoriasis (GPP) Market Emerging Trends and Growth Prospects …
Introduction
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP is less common but often far more severe, requiring urgent treatment and long-term disease management.
With increasing awareness, advances in biologics, and the emergence of targeted therapies specifically developed for GPP, the global market is entering a transformative phase. Over the next decade, pharmaceutical…
Psoriasis Biologics Drugs Market is Set to Experience a Revolutionary Growth
The global psoriasis biologics market is projected to be valued at approximately $26.5 billion in 2024, driven by an increasing prevalence of psoriasis and a growing preference for targeted biologics over traditional therapies. By 2034, the market is expected to reach around $60 billion, reflecting the rising demand for more effective and personalized treatment options.
Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and…
